Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia
Status:
Completed
Trial end date:
2018-12-17
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled study designed to
evaluate the efficacy and safety of intramuscular (IM) injections of Risperidone ISM® (75 or
100 mg) or placebo, in patients with acute exacerbation of schizophrenia.